Skip to Content
Merck
  • Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response.

Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response.

Infection and immunity (2014-06-11)
Claire Legendre, F Jerry Reen, David F Woods, Marlies J Mooij, Claire Adams, Fergal O'Gara
ABSTRACT

Gastroesophageal reflux (GER) frequently occurs in patients with respiratory disease and is particularly prevalent in patients with cystic fibrosis. GER is a condition in which the duodenogastric contents of the stomach leak into the esophagus, in many cases resulting in aspiration into the respiratory tract. As such, the presence of GER-derived bile acids (BAs) has been confirmed in the bronchoalveolar lavage fluid and sputum of affected patients. We have recently shown that bile causes cystic fibrosis-associated bacterial pathogens to adopt a chronic lifestyle and may constitute a major host trigger underlying respiratory infection. The current study shows that BAs elicit a specific response in humans in which they repress hypoxia-inducible factor 1α (HIF-1α) protein, an emerging master regulator in response to infection and inflammation. HIF-1α repression was shown to occur through the 26S proteasome machinery via the prolyl hydroxylase domain (PHD) pathway. Further analysis of the downstream inflammatory response showed that HIF-1α repression by BAs can significantly modulate the immune response of airway epithelial cells, correlating with a decrease in interleukin-8 (IL-8) production, while IL-6 production was strongly increased. Importantly, the effects of BAs on cytokine production can also be more dominant than the bacterium-mediated effects. However, the effect of BAs on cytokine levels cannot be fully explained by their ability to repress HIF-1α, which is not surprising, given the complexity of the immune regulatory network. The suppression of HIF-1 signaling by bile acids may have a significant influence on the progression and outcome of respiratory disease, and the molecular mechanism underpinning this response warrants further investigation.

MATERIALS
Product Number
Brand
Product Description

Cholic acid, European Pharmacopoeia (EP) Reference Standard
Chenodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Cholic acid, from bovine and/or ovine, ≥98%
Sigma-Aldrich
Sodium taurodeoxycholate hydrate, ≥95% (HPLC)
Sigma-Aldrich
Chenodeoxycholic acid
Sigma-Aldrich
Sodium glycodeoxycholate, BioXtra, ≥97% (HPLC)
Supelco
L-Glutamine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Glutamine
Supelco
L-Glutamine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Deoxycholic acid, ≥99.0% (T)
Sigma-Aldrich
Sodium taurocholate hydrate, ≥97.0% (TLC)
SAFC
L-Glutamine
Sigma-Aldrich
Sodium glycocholate hydrate, ≥95% (TLC)
Sigma-Aldrich
Sodium deoxycholate, ≥97% (titration)
Sigma-Aldrich
Sodium cholate hydrate, suitable for cell culture, BioReagent
Sigma-Aldrich
L-Glutamine, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Sodium taurochenodeoxycholate
Sigma-Aldrich
L-Glutamine, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
L-Glutamine, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Sodium chenodeoxycholate, ≥97%
Sigma-Aldrich
Sodium glycochenodeoxycholate
Sigma-Aldrich
Deoxycholic acid, ≥98% (HPLC)
Sigma-Aldrich
L-Glutamine, BioUltra, ≥99.5% (NT)